US2012252840A1PendingUtilityA1
Method of Treating Cancer
Est. expiryApr 4, 2031(~4.7 yrs left)· nominal 20-yr term from priority
A61K 31/47A61P 35/00A61P 35/04
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.
Claims
exact text as granted — not AI-modified1 . A method for treating melanoma, comprising administering to a patient in need of such treatment a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is halo;
R 2 is halo;
R 3 is (C 1 -C 6 )alkyl;
R 4 is (C 1 -C 6 )alkyl; and
Q is CH or N.
2 . The method of claim 1 , wherein the melanoma is ocular melanoma.
3 . The method of claim 1 , wherein the ocular melanoma is choroidal or iris melanoma.
4 . The method of claim 1 , wherein, the dual MET and VEGF modulator is a compound of Formula Ia:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is halo;
R 2 is halo; and
Q is CH or N.
5 . The method of claim 1 , wherein the compound of Formula I is Compound 1:
or a pharmaceutically acceptable salt thereof.
6 . The method of claim 5 , wherein Compound 1 is the (L)- or (D)-malate salt.
7 . The method of claim 6 , wherein Compound 1 is in the crystalline N-1 form.
8 . The method of claim 1 , wherein the compound of Formula I, I(a), or Compound 1, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent.
9 . A method for treating ocular melanoma comprising administering to a patient in need of such treatment Compound 1 or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.